evaluated the association between FcγR polymorphisms and clinical outcomes in a cohort of 15 operable and 35 metastatic HER2+ BC patients treated with chemotherapy and trastuzumab in a prospective study (21). The gene discussed is FCGR2A; the disease is breast cancer.